Literature DB >> 2467703

Combined and sequential effects of human IL-3 and GM-CSF on the proliferation of CD34+ hematopoietic cells from cord blood.

S Saeland1, C Caux, C Favre, V Duvert, M J Pébusque, P Mannoni, J E deVries.   

Abstract

The proliferative effects of recombinant human interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were investigated in semi-solid and liquid cultures of purified CD34+ hematopoietic cells obtained from umbilical cord blood. No important differences in overall cloning efficiencies in response to IL-3 or GM-CSF were observed in semi-solid medium in the presence of erythropoietin (Ep). However, GM-CSF was less effective for the development of erythroid bursts (BFU-E), and only IL-3 was observed to induce significant numbers of mixed-erythroid colonies (E-MIX). Both IL-3 and GM-CSF also induced proliferation of CD34+ in liquid cultures. Proliferative responses to IL-3 were found to be more rapid and stronger than to GM-CSF, although the number of initial responsive cells as judged by autoradiography were comparable. Enhanced proliferation of CD34+ cells both in semi-solid and liquid cultures was obtained in the presence of combinations of IL-3 and GM-CSF. The responses observed were less than additive, with the exception of the development of eosinophil colonies and clusters, where IL-3 and GM-CSF were found to act synergistically. In secondary cultures, proliferative responses to GM-CSF were strongly enhanced by preculture of CD34+ cells in IL-3 for four to 11 days, and to a lesser extent by preculture in GM-CSF. Finally, responses to IL-3 were not affected by preculture of CD34+ cells in the presence of GM-CSF. Our results indicate that there is a wide overlap of cells capable of proliferating either in response to IL-3 or to GM-CSF within the cord blood CD34+ compartment. However, differences in primary proliferation kinetics and increased responsiveness to GM-CSF following preculture suggest the importance of a sequential action of IL-3 and GM-CSF in the expansion of CD34+ cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2467703

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Comparative analysis of the influences of IL-1, IL-3 and GM-CSF on the commitment of granulocyte-macrophage progenitors in vitro.

Authors:  J Maciejewski; H Weber; K Neuhaus; M Wächter; E Elstner; F R Seiler; H D Volk
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  An optimized protocol for the generation and functional analysis of human mast cells from CD34+ enriched cell populations.

Authors:  Yuzhi Yin; Yun Bai; Ana Olivera; Avanti Desai; Dean D Metcalfe
Journal:  J Immunol Methods       Date:  2017-06-16       Impact factor: 2.303

4.  Interleukin-3 in combination with granulocyte-macrophage-colony-stimulating factor following bone marrow transplantation in a radiation accident victim.

Authors:  A Nagler; E Naparstek; P Drakos; C Brautbar; M Goldman; O Kaplan; A Fridmann; S Slavin
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

Review 5.  Eosinophils in the 1990s: new perspectives on their role in health and disease.

Authors:  A J Wardlaw
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

Review 6.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

7.  Interleukin 4 inhibits in vitro proliferation of leukemic and normal human B cell precursors.

Authors:  D Pandrau; S Saeland; V Duvert; I Durand; A M Manel; M T Zabot; N Philippe; J Banchereau
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

8.  Interleukin-3, interleukin-6, granulocyte-macrophage colony-stimulating factor and erythropoietin cord blood levels of preterm and term neonates.

Authors:  B Meister; M Herold; A Mayr; M Widschwendter; H Maurer; K Heim; W Sperl
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

9.  Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

Authors:  M W Dercksen; K Hoekman; W W ten Bokkel Huinink; E M Rankin; R Dubbelman; H van Tinteren; J Wagstaff; H M Pinedo
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.